

# Beate Wieseler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4080772/publications.pdf>

Version: 2024-02-01

20  
papers

1,473  
citations

706676

14  
h-index

759306

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1682  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 341, c4737-c4737.	2.4	456
2	Reporting bias in medical research - a narrative review. <i>Trials</i> , 2010, 11, 37.	0.7	361
3	Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data. <i>PLoS Medicine</i> , 2013, 10, e1001526.	3.9	111
4	Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. <i>BMJ: British Medical Journal</i> , 2012, 344, d8141-d8141.	2.4	88
5	Pathways to independence: towards producing and using trustworthy evidence. <i>BMJ, The</i> , 2019, 367, l6576.	3.0	79
6	New drugs: where did we go wrong and what can we do better?. <i>BMJ: British Medical Journal</i> , 2019, 366, l4340.	2.4	74
7	Generating comparative evidence on new drugs and devices before approval. <i>Lancet, The</i> , 2020, 395, 986-997.	6.3	59
8	Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. <i>BMJ, The</i> , 2020, 370, m2288.	3.0	39
9	Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. <i>BMJ, The</i> , 2015, 350, h796-h796.	3.0	38
10	Finding studies on reboxetine: a tale of hide and seek. <i>BMJ: British Medical Journal</i> , 2010, 341, c4942-c4942.	2.4	28
11	Reporting a Systematic Review. <i>Chest</i> , 2010, 137, 1240-1246.	0.4	25
12	Early benefit assessment of new drugs in Germany – Results from 2011 to 2012. <i>Health Policy</i> , 2014, 116, 147-153.	1.4	25
13	Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. <i>Biometrical Journal</i> , 2016, 58, 43-58.	0.6	25
14	Access to regulatory data from the European Medicines Agency: the times they are a-changing. <i>Systematic Reviews</i> , 2012, 1, 50.	2.5	14
15	Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews. <i>PLoS ONE</i> , 2014, 9, e92067.	1.1	14
16	ENDPOINTS FOR RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 508-513.	0.2	11
17	Secrecy or transparency? The future of regulatory trial data. <i>Cmaj</i> , 2017, 189, E185-E186.	0.9	5
18	Beyond journal publications – a new format for the publication of clinical trials. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2017, 120, 3-8.	0.7	3

#	ARTICLE	IF	CITATIONS
19	From publication bias to lost in information: why we need a central public portal for clinical trial data. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 74-76.	1.7	3
20	Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information. <i>Journal of European CME</i> , 2021, 10, 1989172.	0.6	1